CG Oncology, Inc., was originally incorporated as a California corporation on September 24, 2010 and was subsequently re-incorporated as a Delaware corporation on November 30, 2017. The Company is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec, a potential bladder retention therapy for bladder cancer patients. Its main drug candidate is in development as an alternative to BCG for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) and is currently undergoing clinical trials in the BCG non-responsive and early stage patient population. 

CGON

CGON Profile